ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individualsdoi:10.1161/CIRCULATIONAHA.124.071071atherosclerotic cardiovascular diseaseepidemiologyN-terminal pro-B-type natriuretic peptidepopulation-basedprimary prevention...
[13]. George Thanassoulis, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014 Apr 14;3(2):e000759. [14].S Matthijs Boekholdt, et al. Association of LDL...
3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L,Chapman MJ, De Backer GG, Delgado V, Ference BA, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemi...
[16] Suzuki N, et al. Risk Factors for Vulnerable Plaque Detected Using Near-Infrared Spectroscopy in Patients Receiving Statin Therapy with No History of Coronary Artery Disease[J].Int Heart J. 2023;64(4):577-583. [1...
of Cardiovascular Risk.1Note that the ACC website (ASCVD Risk Estimator Plus) includes additional input variables (diastolic blood pressure, LDL cholesterol, aspirin, statin, etc.) that are not components of the 10-year ASCVD risk calculation but are used for other components of the ACC web...
Interpretation of NLA scientific statement on statin intolerance:a new definition and key considerations for ASCVD risk reduction in the statin intolerant patients 引用 收藏 分享 摘要 2022年6月,美国脂质学会发布《NLA 2022降低他汀类药物不耐受患者ASCVD风险的新定义和关键考虑因素》,提供了他汀类药物不耐受的...
To the Editor Using a microsimulation model, Dr Pandya and colleagues1 found that it was cost-effective to treat more than 60% of all US adults aged 40 through 75 years with a generic statin for primary prevention of atherosclerotic cardiovascular disease (ASCVD). Using a weighted average of ...
To summarize if there were seen 1 week prior to their first ACS events, 51% of them were not recommended for statin therapy based on their ASCVD risk score and 67% of patients either had no chest pain until the event or chest pain within 48hrs of onset of their ACS and consequently ...
Individuals without clinical ASCVD or diabetes who are 40 to 75 years of age with LDL 70 to 189 mg/dL and a 10-year ASCVD risk of 5-7.5% or higherAs shown above, among patients who do not otherwise have a compelling indication for statin therapy, the Pooled Cohort Equations can be us...
For example, liver function tests and kidney function tests help pharmacists determine which statin is most appropriate. In the community pharmacy setting, access to labs and lab data is difficult, meaning all patients with borderline risk or greater had to be referred to their primary care ...